Dose painting to treat single-lobe prostate cancer with hypofractionated high-dose radiation using targeted external beam radiation: Is it feasible? - Abstract

Targeted focal therapy strategies for treating single-lobe prostate cancer are under investigation.

In this planning study, we investigate the feasibility of treating a portion of the prostate to full-dose external beam radiation with reduced dose to the opposite lobe, compared with full-dose radiation delivered to the entire gland using hypofractionated radiation. For 10 consecutive patients with low- to intermediate-risk prostate cancer, 2 hypofractionated, single-arc volumetric-modulated arc therapy (VMAT) plans were designed. The first plan (standard hypofractionation regimen [STD]) included the entire prostate gland, treated to 70Gy delivered in 28 fractions. The second dose painting plan (DP) encompassed the involved lobe treated to 70Gy delivered in 28 fractions, whereas the opposing, uninvolved lobe received 50.4Gy in 28 fractions. Mean dose to the opposing neurovascular bundle (NVB) was considerably lower for DP vs STD, with a mean dose of 53.9 vs 72.3Gy (p < 0.001). Mean penile bulb dose was 18.6Gy for DP vs 19.2Gy for STD (p = 0.880). Mean rectal dose was 21.0Gy for DP vs 22.8Gy for STD (p = 0.356). Rectum V70 (the volume receiving ≥70Gy) was 2.01% for DP vs 2.74% for STD (p = 0.328). Bladder V70 was 1.69% for DP vs 2.78% for STD (p = 0.232). Planning target volume (PTV) maximum dose points were 76.5 and 76.3Gy for DP and STD, respectively (p = 0.760). This study demonstrates the feasibility of using VMAT for partial-lobe prostate radiation in patients with prostate cancer involving 1 lobe. Partial-lobe prostate plans appeared to spare adjacent critical structures including the opposite NVB.

Written by:
Amini A, Westerly DC, Waxweiler TV, Ryan N, Raben D.   Are you the author?
Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO.  

Reference: Med Dosim. 2015 Mar 27. pii: S0958-3947(15)00024-2.
doi: 10.1016/j.meddos.2015.02.002

PubMed Abstract
PMID: 25824420 Prostate Cancer Section